| scholarly article | Q13442814 |
| P2093 | author name string | Bibiana Bielekova | |
| P2860 | cites work | Daclizumab rapidly saturates interleukin-2 receptor-alpha (CD25) on lymph node lymphocytes in children | Q74617252 |
| The use of antibodies against the IL-2 receptor in transplantation | Q77485579 | ||
| Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers | Q78404451 | ||
| Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment | Q78409843 | ||
| Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody | Q80896193 | ||
| CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation | Q80967934 | ||
| The structure of interleukin-2 complexed with its alpha receptor | Q81810296 | ||
| Liver grafts contain a unique subset of natural killer cells that are transferred into the recipient after liver transplantation | Q84488242 | ||
| Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis | Q84565920 | ||
| Daclizumab for relapsing remitting multiple sclerosis | Q24200496 | ||
| Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor | Q24312136 | ||
| Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting | Q24318910 | ||
| Structural basis for NKG2A/CD94 recognition of HLA-E. | Q24336854 | ||
| A humanized antibody that binds to the interleukin 2 receptor | Q24600912 | ||
| Natural killer cells and autoimmunity | Q24793284 | ||
| IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells | Q28214975 | ||
| Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors | Q28282381 | ||
| Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment | Q28587823 | ||
| Cytotoxicity of CD56(bright) NK cells towards autologous activated CD4+ T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94/NKG2A | Q28731856 | ||
| Risk alleles for multiple sclerosis identified by a genomewide study | Q29614890 | ||
| Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration | Q33194554 | ||
| NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis | Q33381309 | ||
| IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production | Q33396971 | ||
| How implementation of systems biology into clinical trials accelerates understanding of diseases. | Q33814843 | ||
| Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. | Q33854381 | ||
| Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death | Q33876302 | ||
| Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. | Q34088526 | ||
| The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. | Q34152180 | ||
| NK cells and NKT cells in innate defense against viral infections | Q34332682 | ||
| The biology of human natural killer-cell subsets | Q34430869 | ||
| Control of T-cell activation by CD4+ CD25+ suppressor T cells | Q34448423 | ||
| Microbiota-induced tertiary lymphoid tissues aggravate inflammatory disease in the absence of RORgamma t and LTi cells | Q34501407 | ||
| Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta | Q34514715 | ||
| Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. | Q34596171 | ||
| CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes | Q34596186 | ||
| Monoclonal antibodies in MS: mechanisms of action | Q34615261 | ||
| The IL-2/IL-15 receptor systems: targets for immunotherapy | Q34630134 | ||
| Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results | Q34665233 | ||
| An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells | Q34893862 | ||
| A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy | Q34949098 | ||
| CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS | Q35023350 | ||
| Human NK cells and their receptors. | Q35035740 | ||
| Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis | Q35091437 | ||
| The main function of IL-2 is to promote the development of T regulatory cells | Q35213797 | ||
| Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis | Q35619174 | ||
| Intrathecal effects of daclizumab treatment of multiple sclerosis | Q35635127 | ||
| Unraveling human natural killer cell deficiency | Q35780328 | ||
| Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors | Q36351101 | ||
| Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial | Q36397083 | ||
| Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization | Q36402763 | ||
| Lymphoid neogenesis in chronic inflammatory diseases. | Q36405080 | ||
| Natural killer cells act as rheostats modulating antiviral T cells | Q36517134 | ||
| Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination | Q36521247 | ||
| Search for organising principles: understanding in systems biology | Q36628523 | ||
| Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis | Q36639659 | ||
| CNS vasculitis in a patient with MS on daclizumab monotherapy | Q36661852 | ||
| Cutaneous adverse events in multiple sclerosis patients treated with daclizumab | Q36691970 | ||
| Maternal acceptance of the fetus: true human tolerance | Q36752550 | ||
| Human natural killer cells | Q36787596 | ||
| Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation | Q36957280 | ||
| IL-2 signaling and CD4+ CD25+ Foxp3+ regulatory T cells. | Q36992146 | ||
| CD226 Gly307Ser association with multiple autoimmune diseases | Q37083069 | ||
| Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. | Q37159538 | ||
| CD25 as an immune regulatory molecule expressed on myeloid dendritic cells | Q37300261 | ||
| Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells | Q37313533 | ||
| Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. | Q37343849 | ||
| Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis | Q37354974 | ||
| Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. | Q37418499 | ||
| Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis | Q37657070 | ||
| Lymphoid tissue inducer cells: innate cells critical for CD4+ T cell memory responses? | Q37977138 | ||
| Increased prevalence of lymphoid tissue inducer cells in the cerebrospinal fluid of patients with early multiple sclerosis | Q38954794 | ||
| Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac | Q39168921 | ||
| Revised nomenclature for antigen-nonspecific T-cell proliferation and helper factors | Q39577528 | ||
| IL-2 receptors in adult T-cell leukemia: a target for immunotherapy | Q39601718 | ||
| Functional and morphologic characterization of human T cells continuously grown in vitro | Q39818384 | ||
| Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis | Q40962718 | ||
| Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response | Q41472662 | ||
| Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells | Q41475516 | ||
| Interleukin-2, interleukin-15, and their receptors | Q41722182 | ||
| Cutting edge: lymphoid tissue inducer cells maintain memory CD4 T cells within secondary lymphoid tissue | Q42325266 | ||
| Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis | Q43539775 | ||
| Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta | Q44597307 | ||
| Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. | Q45840886 | ||
| IL-2 receptor alpha(-/-) mice and the development of primary biliary cirrhosis | Q46106529 | ||
| Granzyme K displays highly restricted substrate specificity that only partially overlaps with granzyme A. | Q46211971 | ||
| Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral blood | Q46655432 | ||
| Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials | Q47242957 | ||
| Anti-CD25 monoclonal antibody therapy affects the death signals of graft-infiltrating cells after clinical heart transplantation. | Q47871733 | ||
| Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. | Q48200750 | ||
| Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial | Q48265627 | ||
| Journal club: Intrathecal effects of daclizumab treatment of multiple sclerosis | Q48491256 | ||
| Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis | Q48949792 | ||
| A role for natural killer cells in the immunopathogenesis of multiple sclerosis. | Q50876710 | ||
| Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. | Q51027456 | ||
| Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. | Q55044269 | ||
| Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosis. | Q55059713 | ||
| CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity | Q57265370 | ||
| Lineage Relationship Analysis of RORγt+Innate Lymphoid Cells | Q57520258 | ||
| Immune responses in interleukin-2-deficient mice | Q58194363 | ||
| Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial | Q62033090 | ||
| Accumulation of CD16−CD56+ natural killer cells with high affinity interleukin 2 receptors in human early pregnancy decidua | Q67700611 | ||
| Cytokine production by CD16–CD56bright natural killer cells in the human early pregnancy decidua | Q72085502 | ||
| Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta | Q72287439 | ||
| Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor | Q72609371 | ||
| Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events | Q73370304 | ||
| Human IL-2 receptor alpha chain deficiency | Q73952904 | ||
| CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells | Q74602353 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | a034470 | |
| P577 | publication date | 2018-04-16 | |
| P1433 | published in | Cold Spring Harbor Perspectives in Medicine | Q21042440 |
| P1476 | title | Daclizumab Therapy for Multiple Sclerosis. | |
| P478 | volume | 9 |
Search more.